Impaired fibrinolysis and risk for cardiovascular disease in the metabolic syndrome and type 2 diabetes

Susanne Trost, Richard E. Pratley, Burton E. Sobel

Research output: Contribution to journalReview article

58 Scopus citations

Abstract

Patients with the metabolic syndrome are insulin resistant and manifest a cluster of risk factors for cardiovascular disease. Impaired fibrinolysis and increased concentrations in blood of plasminogen activator inhibitor-I (PAI-I) are related to insulin resistance and abdominal obesity and may contribute to the increased risk for cardiovascular disease in this group. Weight loss, metformin, and thiazolidinediones ameliorate insulin resistance and decrease concentrations of PAI-I. Thus, they may lower risk in patients with the metabolic syndrome.

Original languageEnglish (US)
Pages (from-to)47-54
Number of pages8
JournalCurrent diabetes reports
Volume6
Issue number1
DOIs
StatePublished - Feb 1 2006
Externally publishedYes

Fingerprint Dive into the research topics of 'Impaired fibrinolysis and risk for cardiovascular disease in the metabolic syndrome and type 2 diabetes'. Together they form a unique fingerprint.

  • Cite this